Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Improved apo e analogs and methods for their use

A technology of use and medicine, applied in the field of improved APO E analogs and its use, can solve the problems of incomplete elucidation, exacerbation, sepsis and other problems of ApoE

Inactive Publication Date: 2015-01-21
CORNERSTONE THERAPEUTICS (SHANGHAI) LTD
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, Hong et al. (1995) reported that tumor necrosis factor α (TNFa), interleukin 1α and 1β (IL1a and IL1b) in the brains of mice receiving a single dose of 25 Gray (Gy) brain irradiation mRNA was significantly elevated and this dose caused less than 10% of deaths
Despite the beneficial effects of ApoE on innate immunity, as evidenced by the fact that ApoE-deficient mice lack innate immunity to systemic infection leading to sepsis and severe exacerbations, the role of ApoE in intestinal inflammation remains incomplete. clarify

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improved apo e analogs and methods for their use
  • Improved apo e analogs and methods for their use
  • Improved apo e analogs and methods for their use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0211] Example 1: Design and Characterization of Improved Peptide Analogs

[0212] Retro Inverso Peptide

[0213] Peptide analogs containing substitutions with D-amino acids for L-amino acids were prepared to study the stereospecificity of ApoE130-150 activity. Applicants compared all L-amino acid peptides to all D-amino acid peptides to test whether retro-inverso analogs of ApoE130-150 were active. The retro-inverso analog is the reverse sequence (ie ApoE150-130), which consists only of D-amino acids (all D ApoE150-130). Unlike the report by Pescarolo et al. (2001), the applicants found that the retro-inverso peptide was incredibly toxic at any concentration above 0.01 micromolar. Therefore, the observed marked reduction in nitric oxide production by BV-2 microglia is an artifact since the cells tested had been killed by this retro-inverso peptide. Furthermore, all-D amino acid analogs of ApoE130-150 did not have the activity of inhibiting the release of nitric oxide (NO) ...

Embodiment 2

[0288] Example 2: Characterization of COG432

[0289] Figure 4 presents the rotarod test results after TBI treated with 4 mg / kg or 1 mg / kg of COG432, (COG432: Ac-ASHLRKLAibKRLL (SEQ ID NO. 6)) or control (saline). The vertical axis is rotarod balance performance (100% is rotarod balance performance prior to TBI). Treatment with COG 4324 mg / kg or saline was initiated 2 hours after traumatic brain injury and animals were tested beginning day 1 post-TBI and daily for 5 days thereafter. On day 5 post-TBI, animals treated with 4 mg / kg of COG432 peptide recovered approximately 80% of their function as determined by the rotarod test. Control mice treated with saline vehicle alone recovered less than 50% of their function.

Embodiment 3

[0290] Example 3: Characterization of COG1410

[0291] COG1410 was synthesized, an analog containing two aminobutyric acid (Aib) substitutions at positions L140 and R145. Aib is an unnatural amino acid that has been found to form a helical conformation independent of the type of amino acid in the peptide (Marshall et al. 1990). Furthermore, Aib increases binding affinity as it exhibits a reduced loss of conformational entropy upon binding relative to other amino acids (Ratnaparkhi et al. 2000).

[0292] Cellular level analysis

[0293] As shown in Figure 7, we found that COG1410 was significantly more potent than COG133 when tested at the cellular level to inhibit the release of nitric oxide (9A) and TNFa (9B). Furthermore, preliminary in vivo screening suggested that COG1410 was neuroprotective when administered 120 minutes after TBI, in contrast COG133 was not neuroprotective at this time point (Figure 8).

[0294] Dose-response study

[0295] Preliminary dose-response s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses novel Apo E peptide derivatives and Apo E-protein transduction domain conjugates, which are useful in the treatment of diseases including CNS inflammation, traumatic brain injury, inflammatory bowel disease (also known as Crohn's disease or Ulcerative colitis), cerebral ischemia, atherosclerosis, sepsis, multiple sclerosis and arthritic diseases, Alzheimer's and other brain diseases. The invention includes methods of protecting a subject undergoing irradiation or radiotherapy by administering Apo E or at least one Apo E mimetic peptide.

Description

[0001] 1. Cross-references to related applications [0002] This application claims priority to provisional applications 60 / 606,506, filed September 2, 2004, 60 / 608,148, filed September 9, 2004, and 60 / 606,507, filed September 2, 2004, at This application is hereby incorporated by reference in its entirety into the present application. This application is also related to applications 09 / 260,430 filed March 1, 1999, 09 / 957,909 filed September 21, 2001, 10 / 252,120 filed September 23, 2002, and March 29, 2005 Filed application 11 / 091,336, which is hereby incorporated by reference in its entirety into this application. 2. Technical field [0003] The present invention relates to compounds and compounds useful in the treatment of traumatic brain injury, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, arthritis, multiple sclerosis, atherosclerosis, and sepsis method. The invention also relates to methods of protecting subjects against the effects of radiati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/00
CPCC07K14/775A61K38/1709A61P1/00A61P1/02A61P1/04A61P11/04A61P13/10A61P17/02A61P17/06A61P17/16A61P19/02A61P25/00A61P25/02A61P25/28A61P29/00A61P31/04A61P37/02A61P39/00A61P43/00A61P9/00A61P9/10Y02A50/30
Inventor 迈克尔·P·维特克苏珊·E·麦克纳克里斯托弗·R·塞尔夫
Owner CORNERSTONE THERAPEUTICS (SHANGHAI) LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com